Table 2.
OR and 95% CI for hepatocellular cancer and rs1128503 or rs1045642 polymorphism in MDR1 under different genetic models.
| Genetic models | n | OR (95% CI) | P (OR) | Analysis model | I2(%) | P(H) | P (Egger) | P (Begg) |
|---|---|---|---|---|---|---|---|---|
| rs1128503 T>C | ||||||||
| Allele (C vs. T) | 4 | 0.91 (0.76, 1.08) | 0.260 | F (M-H) | 42.8 | 0.155 | 0.082 | 0.308 |
| Homozygous model (CC vs. TT) | 4 | 0.80 (0.57, 1.12) | 0.193 | F (M-H) | 46.2 | 0.134 | 0.225 | 0.308 |
| Heterozygous model (CT vs. TT) | 4 | 0.77 (0.56, 1.04) | 0.093 | F (M-H) | 40.5 | 0.169 | 0.914 | 1.000 |
| Recessive model (CC vs. CT+TT) | 4 | 0.95 (0.73, 1.25) | 0.729 | F (M-H) | 19.1 | 0.295 | 0.230 | 0.734 |
| Dominant model (CC+CT vs. TT) | 4 | 0.81 (0.61, 1.07) | 0.137 | F (M-H) | 48.5 | 0.120 | 0.592 | 0.734 |
| rs1045642 T>C | ||||||||
| Allele (C vs. T) | 3 | 1.10 (0.83, 1.45) | 0.505 | F (M-H) | 0 | 0.435 | 0.293 | 1.000 |
| Homozygous model (CC vs. TT) | 3 | 1.16 (0.67, 2.01) | 0.587 | F (M-H) | 0 | 0.421 | 0.100 | 0.296 |
| Heterozygous model (CT vs. TT) | 3 | 0.93 (0.55, 1.60) | 0.800 | F (M-H) | 29.2 | 0.243 | 0.755 | 1.000 |
| Recessive model (CC vs. CT+TT) | 3 | 1.21 (0.81, 1.80) | 0.354 | F (M-H) | 0 | 0.660 | 0.481 | 0.296 |
| Dominant model (CC+CT vs. TT) | 3 | 1.01 (0.62, 1.65) | 0.962 | F (M-H) | 30.3 | 0.238 | 0.450 | 1.000 |
OR, odds ratio; CI, confidence interval; P(OR), probability for odds ratio; P(H), P for heterogeneity; n, number of the included studies; F, fixed-effect model; M-H, Mantel-Haenszel method.